Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AMG-609 by Amgen for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
AMG-609 is under clinical development by Amgen and currently in Phase I for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). According...